Johnson & Johnson Statement On Investigational Programs In Large B-cell Lymphoma; To Discontinue CD20 And CD19-CD20 CAR-T Programs; To Continue Support For Patients In Discontinued Investigational CD20 Mono CAR-T Cell Therapy And CD19-CD20 bi-CAR-T Programs